Celsion (NASDAQ:CLSN) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

A number of other analysts have also recently weighed in on CLSN. Zacks Investment Research cut Celsion from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Oppenheimer assumed coverage on Celsion in a research note on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $11.90.

How to Become a New Pot Stock Millionaire

Shares of CLSN stock opened at $2.48 on Wednesday. Celsion has a 52 week low of $1.24 and a 52 week high of $6.06.

An institutional investor recently bought a new position in Celsion stock. Virtu Financial LLC purchased a new stake in Celsion Co. (NASDAQ:CLSN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned approximately 0.24% of Celsion at the end of the most recent reporting period. 3.84% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Celsion (CLSN) Stock Rating Upgraded by ValuEngine” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.watchlistnews.com/celsion-clsn-stock-rating-upgraded-by-valuengine/1959717.html.

Celsion Company Profile

Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.